QLT Announces First Quarter 2015 Results

VANCOUVER, British Columbia, April 30, 2015 (SATPRNEWS.COM) — QLT Inc. (Nasdaq:QLTI) (TSX:QLT) (“QLT” or the “Company”) is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. The Company reported financial results today for the first quarter ended March 31, 2015. Unless otherwise specified, all amounts Continue Reading

Cellular Biomedicine Group Appoints Two New Members to Scientific Advisory Board

PALO ALTO, Calif., April 30, 2015 (SATPRNEWS.COM) — Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies for cancer, today announced the appointment of Scott J. Antonia, M.D, Ph.D. and Guoping Fan, Ph.D., as members of the newly established Scientific Advisory Board. Dr. Continue Reading

Commercial Electronic Flight Bag Market Worth $4.27 Billion by 2020

DALLAS, April 30, 2015 /SATPR.COM/ – According to a new market research report “Commercial Electronic Flight Bag Market by Type (Portable EFB and Installed EFB), Component (Hardware: Class 1, Class 2, and Class 3, Software: Type A, Type B, and Type C), and by Geography – Forecast 2015 to 2020“, published by MarketsandMarkets, the commercial Electronic Flight Bag Market forecasted Continue Reading

Chicago-Area Startup Poised To Bring Massage Into The Digital Age

CHICAGO, April 30, 2015 /SATPR.COM/ — Excel Mobile Massage (EMM) is a new company that caters to the busy lifestyles of Chicagoans desiring a massage on their terms.  “We see a real opportunity in Chicago to create a better massage experience for customers.  People expect technology to make their lives simpler.  Clients want the convenience to book online or on an Continue Reading

Advaxis Prices $53 Million Public Offering of Common Stock

PRINCETON, N.J., April 30, 2015 (SATPRNEWS.COM) — Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage cancer immunotherapy company, today announced the pricing of its previously announced underwritten public offering of 2,800,000 shares of its common stock at a public offering price of $19.00 per share. Advaxis has also granted the underwriters a 30-day option to purchase up to an additional 420,000 shares of Continue Reading